Orthovita applies for CE mark for Cortoss filler:
This article was originally published in Clinica
Orthovita has applied for European marketing clearance for its Cortoss Injectable bone void filler. The application includes the results of a 24-patient multicentre study of patients undergoing surgery to repair bone fractures that showed the product allowed metal screws to be used in 98% of situations in which bone screws had previously failed because of the patients' poor bone quality. Approximately 1.5 million orthopaedic procedures involving internal fixation devices that require screwing are performed worldwide each year, 10% of which fail to hold because of poor bone quality, said Malvern, Pennsylvania-based Orthovita.
You may also be interested in...
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.